62 results
SC 14D9/A
PNT
POINT Biopharma Global Inc.
1 Nov 23
Tender offer solicitation (amended)
4:40pm
as follows:
“Analyst Price Target Analysis. Centerview reviewed stock price targets for the Shares in ten (10) publicly available Wall Street research … analyst reports as of October 2, 2023, which indicated low and high stock price targets for POINT ranging from $11.00 to $27.00 per Share and a median
SC 14D9
PNT
POINT Biopharma Global Inc.
13 Oct 23
Tender offer solicitation
7:11am
Analysis. Centerview reviewed stock price targets for the Shares in publicly available Wall Street research analyst reports as of October 2, 2023, which … indicated low and high stock price targets for POINT ranging from $11.00 to $27.00 per Share.
Premiums Paid Analysis. Centerview performed
ARS
c4kxvk6ipcd0de
1 May 23
Annual report to shareholders
1:52pm
424B5
k4d3k5yq
14 Sep 22
Prospectus supplement for primary offering
4:12pm
424B5
v0wjah5 unlem1b8o2km
13 Sep 22
Prospectus supplement for primary offering
5:19pm
S-3
5m5i26ca
1 Jul 22
Shelf registration
4:13pm
DEF 14A
3tz238k
28 Apr 22
Definitive proxy
8:36am
424B3
89s8hisr4hogbc t990f
31 Mar 22
Prospectus supplement
11:42am
POS AM
twbyhcm
25 Mar 22
Prospectus update (post-effective amendment)
8:41am
8-K
EX-99.1
d4e l7b5imeuo9dwv
25 Mar 22
POINT Biopharma Reports Fiscal 2021 Financial Results and Provides Business Update
8:22am
424B3
EX-99.1
n66yf4kxa2pkr
25 Feb 22
Prospectus supplement
8:39am
8-K
EX-99.1
gcwr1d0
25 Feb 22
Regulation FD Disclosure
8:38am
424B3
EX-99.1
bu4sy
1 Dec 21
Prospectus supplement
8:25am